Show simple item record

dc.contributor.authorHamilton, RJ
dc.contributor.authorDing, K
dc.contributor.authorCrook, JM
dc.contributor.authorO'Callaghan, CJ
dc.contributor.authorHigano, CS
dc.contributor.authorDearnaley, DP
dc.contributor.authorHorwitz, EM
dc.contributor.authorGoldenberg, SL
dc.contributor.authorGospodarowicz, MK
dc.contributor.authorKlotz, L
dc.date.accessioned2021-02-22T11:35:12Z
dc.date.available2021-02-22T11:35:12Z
dc.date.issued2020-12-31
dc.identifier.citationEuropean urology, 2020en_US
dc.identifier.issn0302-2838
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4354
dc.identifier.eissn1873-7560en_US
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.eissn1873-7560
dc.identifier.doi10.1016/j.eururo.2020.12.031en_US
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.identifier.doi10.1016/j.eururo.2020.12.031
dc.description.abstract<h4>Background</h4>Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report positive results, with a few specifically examining statins and androgen deprivation therapy (ADT).<h4>Objective</h4>To perform a post hoc secondary analysis of a randomised controlled trial (RCT) of men initiating ADT to examine the association between statin use and outcomes.<h4>Design, setting, and participants</h4>Patients with prostate-specific antigen (PSA) >3 ng/ml >1 yr following primary/salvage radiotherapy were enrolled in an RCT of intermittent androgen deprivation (IAD) versus continuous ADT (NCT00003653). Baseline and on-study statin use was modelled as a time-dependent covariate.<h4>Outcome measurements and statistical analysis</h4>The primary endpoint was overall survival. Models were adjusted for age, time from radiotherapy to ADT, baseline PSA, and prior ADT.<h4>Results and limitations</h4>Of 1364 patients, statin users (585; 43%) were younger (72.7 vs 73.8 yr, p = 0.001) and less likely to have PSA >15 ng/ml (20% vs 25%, p = 0.04). After a median follow-up of 6.9 yr, statin use was associated with reduced overall (hazard ratio [HR]: 0.64; 95% confidence interval [CI] 0.53-0.78, p < 0.001) and PCa-specific (HR: 0.65, 95% CI 0.48-0.87, p = 0.004) mortality. Statin users had 13% longer time to castration resistance, but this did not reach statistical significance (p = 0.15). As an exploratory endpoint, in the IAD arm, statin users had longer time off treatment (median: 0.85 vs 0.64 yr, p = 0.06). Limitations include potential for residual confounding between statin users and nonusers, and confounding by indication.<h4>Conclusions</h4>In men treated with ADT following primary or salvage radiotherapy, statin use was associated with improved overall and PCa-specific survival. In patients treated with IAD, statin use was associated with a trend towards longer time off treatment. A prospective trial of statins in men commencing ADT is warranted.<h4>Patient summary</h4>We found a favourable association between statin use and survival outcomes in patients initiating androgen deprivation therapy.en_US
dc.formatPrint-Electronicen_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleThe Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-12-17
rioxxterms.versionAMen_US
rioxxterms.versionofrecord10.1016/j.eururo.2020.12.031en_US
rioxxterms.licenseref.startdate2020-12-31
dc.relation.isPartOfEuropean urologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.publication-statusPublisheden_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Dearnaley)
dc.contributor.icrauthorDearnaley, Daviden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record